Ditekiren

Summary

Ditekiren is an investigational peptidomimetic renin inhibitor developed in the late 1980s and early 1990s. It was studied as an antihypertensive agent but never reached clinical approval. It demonstrated potent in vitro and in vivo renin inhibition and served as a key tool compound in validating renin as a therapeutic target, contributing to the later development of aliskiren.

Mechanism of Action

Competitive inhibitor of renin, the aspartyl protease that cleaves angiotensinogen to angiotensin I. By blocking renin, ditekiren reduces angiotensin I and II formation, lowering blood pressure via suppression of the renin-angiotensin-aldosterone system (RAAS).

Routes of Administration

Goals & Uses

• Blood pressure reductionCardiovascularModerate
• Renin inhibition (pharmacological probe)ResearchHigh
• RAAS characterizationResearchHigh

Contraindications

• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Concurrent use with ACE inhibitors or ARBs in diabetic patientsDrug InteractionModerate
• Known hypersensitivity to ditekiren or excipientsAllergyHigh

Adverse Effects

• Injection site reactionsLocalCommon
• HypotensionCardiovascularUncommonLow blood pressure
• Renal function impairmentRenalRare
• HyperkalemiaElectrolyte ImbalanceUncommon

Drug Interactions

• Angiotensin Receptor Blockers (ARBs)Moderate
• ACE inhibitorsModerate
• Potassium-sparing diureticsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Patients with severe renal artery stenosisRenalAbsolute
• Pregnant womenReproductiveAbsolute
• Volume-depleted patientsCardiovascularRelative

Regulatory Status

• European UnionUnapprovedNever received EMA review; research compound only.
• United StatesUnapprovedNever submitted to FDA; research compound only.
• United KingdomUnapprovedNo MHRA submission; remains a research tool compound.

Ditekiren was never submitted for regulatory approval in any jurisdiction. It remains a research compound used primarily to characterize renin inhibitor pharmacology.

Evidence & Sources

No sources recorded yet.